Navigation Links
OncoGenex Announces Publication of Custirsen Phase II Clinical and Pre-Clinical Data in Leading Cancer Journals
Date:9/6/2011

tify opportunities to block these mechanisms in order to delay tumor progression."

The abstract can be found at the following link:

http://cancerres.aacrjournals.org/content/71/17/5838.abstract

About Custirsen

Custirsen is the only compound currently in development designed to inhibit the production of clusterin, a protein commonly over-produced in cancer cells, and one cause of treatment resistance. Unlike opioids or agents that target the androgen receptor, custirsen is mechanistically unique in its ability to impact pain responses via the regulation of NF-kB (nuclear factor kappa-light-chain-enhancer of activated B cells) activity.  This is a potential attribute that could contribute to custirsen's clinical benefit in combination with numerous anti-cancer treatments.

Custirsen has received Fast Track designation from the U.S. Food and Drug Administration (FDA).

More information is available at www.OncoGenex.com and www.tevapharm.com/research.

About OncoGenex Pharmaceuticals

OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NASDAQ:  TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase III clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase III development of custi
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related biology technology :

1. OncoGenex Pharmaceuticals Names Michelle Burris Executive Vice President, Operations and Chief Financial Officer
2. OncoGenex Reports Third Quarter Financial Results
3. OncoGenex Pharmaceuticals, Inc. Closes $50 Million Public Offering
4. OncoGenex Pharmaceuticals, Inc. Prices $50 Million Public Offering
5. OncoGenex Pharmaceuticals, Inc. Announces Proposed Public Offering
6. OncoGenex Pharmaceuticals to Present at the 9th Annual BIO Investor Forum
7. TEVA AND ONCOGENEX ANNOUNCE INITIATION OF SECOND PHASE 3 TRIAL OF CUSTIRSEN IN MEN WITH METASTATIC PROSTATE CANCER
8. OncoGenex Pharmaceuticals, Inc. - Journal of Clinical Oncology Publishes Data from Randomized Phase 2 Custirsen Trial
9. OncoGenex Reports Second Quarter Financial Results
10. OncoGenex Pharmaceuticals Announces Initiation of a Phase 3 Trial in Men with Metastatic Prostate Cancer
11. OncoGenex Pharmaceuticals to Present at the 9th Annual Needham Healthcare Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/14/2014)... Boston, MA (PRWEB) January 14, 2014 iLab ... Michelle Detwiler as the new Director of Product Strategy. In ... as well as iLab sub-teams to guide in the development ... that iLab provides the maximum possible benefit to the scientific ...
(Date:1/14/2014)... January 14, 2014 Global Record ... innovative information technology solutions for patients, physicians, the ... stakeholders, announced today the signing of a three-year ... and Drug Administration (FDA). This initiative is ...
(Date:1/14/2014)... Kerr Corporation, a leading manufacturer of innovative dental ... about dual arch impressions on its dental blog. ... blog entry serves up a list of tips to help ... by Dr. David Little as he crafts a porcelain crown ...
(Date:1/14/2014)... BioMedomics, Inc. , a Point of Care ... novel disease specific POC tests, announced today that it has ... of $690,000. The investment is from private investors and is ... of private investors has significant successful experience in early investments ...
Breaking Biology Technology:iLab Solutions Announces Michelle Detwiler as the New Director of Product Strategy 2Global Record Systems Announces Research Collaboration Agreement with FDA to Create a Novel “Big Data” Paradigm for Collection of Patient Safety and Outcomes Information 2BioMedomics, Inc. Closes $690K Round of Financing 2
... , - Covance experts to present best practices for improving ... , PRINCETON, N.J., June 16 Covance Inc. is pleased ... at the Drug Information Association,s (DIA) 45th Annual ... Calif. , , The DIA Annual ...
... Relationship increases access to testing for sleep-related illnesses , ... a California-based provider of in-home sleep testing and Continuous ... with Aetna, one of the nation,s largest healthcare benefit ... will now be able to serve more patients with ...
... , , , PHILADELPHIA, June 16 ... as Pew Latin American Fellows in the Biomedical Sciences. The ... level scientists to work with leading researchers in the United ... $35,000 to purchase essential equipment to continue their research in ...
Cached Biology Technology:Covance to Present at the Drug Information Association's 45th Annual Meeting 2Covance to Present at the Drug Information Association's 45th Annual Meeting 3Covance to Present at the Drug Information Association's 45th Annual Meeting 4Covance to Present at the Drug Information Association's 45th Annual Meeting 5SleepQuest Signs National Contract With Aetna 2Ten Top Latin American Scientists Named 2009 Pew Fellows in the Biomedical Sciences 2Ten Top Latin American Scientists Named 2009 Pew Fellows in the Biomedical Sciences 3
(Date:4/17/2014)... NY, April 17, 2014The development of stem cell therapies ... ability to characterize stem cell populations based on cell ... discovered a new marker that is highly expressed in ... cord blood, which they describe in an article in ... Mary Ann Liebert, Inc., publishers. The article is available ...
(Date:4/17/2014)... N.M. A credit-card-sized anthrax detection cartridge developed at ... business makes testing safer, easier, faster and cheaper. ... anthrax, is commonly found in soils all over the ... in both humans and animals. The bacteria can survive ... B. anthracis may occur through skin contact, ...
(Date:4/17/2014)... need to produce hydrogen sulfide in order to properly ... study from the Center for Craniofacial Molecular Biology at ... Professor Songtao Shi, principal investigator on the project, said ... governs the flow of calcium ions. The essential ions ... osteogenesis, or the creation of new bone tissue, and ...
Breaking Biology News(10 mins):Pocket-sized anthrax detector aids global agriculture 2Pocket-sized anthrax detector aids global agriculture 3
... 2011 -- Scientists from the University of Miami (UM) Rosenstiel ... national research team to find two plumes of oil-based pollutants ... a study published in this week,s issue of the journal ... the mechanism by which the crude oil traveled from the ...
... As evidence regarding the health benefits of consuming ... increasing debate about which cocoa and chocolate products deliver ... steps in cocoa and chocolate production diminish the levels ... published paper, scientists reported on the effect of conventional ...
... in French . The Universit de ... the Botanical Garden. The new Centre, the result of a ... Montral Insectarium, two Espace pour la vie (Montral Space for ... its preservation and its promotion. The Centre will not only ...
Cached Biology News:New study reveals aerosol plumes downwind of the Deepwater Horizon oil spill 2Study clarifies the role of cocoa bean handling on flavanol levels 2The University of Montreal Biodiversity Centre opens 2The University of Montreal Biodiversity Centre opens 3
... Safe photographic filter (S37100, Photographic Filters ... is ideal for black-and-white photography of ... DNA gel stain, the safer ethidium ... Safe photographic filter is identical to ...
... Sensitivity Freezing Point Osmometer for 10 ... volume applications, including pediatric, neonatal, geriatric, ... Automatic Calibration with 2 or ... printer, keypad and software for statistical ...
...
Ultra Pure Grade. Used in conjunction with IPTG to identify bacterial colonies that contain recombinant plasmids by blue/white selection. X-Gal forms an intense blue precipitate in the presence of be...
Biology Products: